Search

November 7, 2024

Nyxoah Reports Third Quarter Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating Results FDA approval on track for first quarter 2025, U.S. commercial team build out in progress Company fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of

Experts propose measures to achieve sustainable targets

Islamabad: Amid sluggish growth and increasing poverty ratio in the country, experts on Wednesday recommended certain measures to policymakers that focused on achieving sustainable targets and plugging loopholes in a number of sectors that impeded eco…